Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Simon

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 5, 2012
Very early MS--insights from MRIJack Simon
Annals of Neurology|June 21, 2006
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal studyRichard A Rudick, Jar-Chi Lee, Jack Simon, et al.
Annals of Neurology|September 25, 2004
Defining interferon beta response status in multiple sclerosis patientsRichard A Rudick, Jar-Chi Lee, Jack Simon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2013
Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patientsSyrone Liu, Jonathan Kullnat, Dennis Bourdette, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Lipoic acid in secondary progressive MS: A randomized controlled pilot trialRebecca Spain, Katherine Powers, Charles Murchison, et al.
The Lancet. Neurology|February 19, 2010
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, Michael Kaufman, Xavier Montalban, et al.
Schizophrenia Research|April 17, 2002
Increased hippocampal volume in schizophrenics' parents with ancestral history of schizophreniaJosette G Harris, David A Young, Donald C Rojas, et al.
Annals of Neurology|October 23, 2009
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker, Paul O'Connor, Mark S Freedman, et al.
Autoimmune Diseases|May 2, 2012
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation StudyVijayshree Yadav, Dennis N Bourdette, James D Bowen, et al.
International Journal of MS Care|January 24, 2014
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010Stuart D Cook, Suhayl Dhib-Jalbut, Peter Dowling, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 5, 2012
Very early MS--insights from MRIJack Simon
Annals of Neurology|June 21, 2006
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal studyRichard A Rudick, Jar-Chi Lee, Jack Simon, et al.
Annals of Neurology|September 25, 2004
Defining interferon beta response status in multiple sclerosis patientsRichard A Rudick, Jar-Chi Lee, Jack Simon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2013
Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patientsSyrone Liu, Jonathan Kullnat, Dennis Bourdette, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 7, 2017
Lipoic acid in secondary progressive MS: A randomized controlled pilot trialRebecca Spain, Katherine Powers, Charles Murchison, et al.
The Lancet. Neurology|February 19, 2010
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, Michael Kaufman, Xavier Montalban, et al.
Schizophrenia Research|April 17, 2002
Increased hippocampal volume in schizophrenics' parents with ancestral history of schizophreniaJosette G Harris, David A Young, Donald C Rojas, et al.
Annals of Neurology|October 23, 2009
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker, Paul O'Connor, Mark S Freedman, et al.
Autoimmune Diseases|May 2, 2012
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation StudyVijayshree Yadav, Dennis N Bourdette, James D Bowen, et al.
International Journal of MS Care|January 24, 2014
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010Stuart D Cook, Suhayl Dhib-Jalbut, Peter Dowling, et al.
Pageof 2